Leiomyosarcoma natural history

Leiomyosarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Leiomyosarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Leiomyosarcoma natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Leiomyosarcoma natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Leiomyosarcoma natural history

CDC on Leiomyosarcoma natural history

Leiomyosarcoma natural history in the news

Blogs on Leiomyosarcoma natural history

Directions to Hospitals Treating Leiomyosarcoma

Risk calculators and risk factors for Leiomyosarcoma natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief:  Nima Nasiri, M.D.[2]

## Overview

[edit | edit source]

Leiomyosarcoma of uterus is an agressive soft tissue tumor which is diagnosed accidentally when they remove fibroid tumor and histology analysis reveal the aggressive nature of tumor. Most common sites that leiomyosarcoma invades are the lungs, liver, abdomen, pelvis, and lymph nodes, bone and brain metastases are less common sites of involvement. Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary, in those that tumor spread beyond uterus and pelvic, prognosis is very poor. Prognosis depends mainly on the age of the patient, race, FIGO stage, mitotic index and hormonal receptor expression in the tumor.

## Natural History

[edit | edit source]

* Most leiomyosarcoma are diagnosed incidentally during hysterectomy of suspected fibroid tumors.[1][2][3]
* A leiomyosarcoma, especially in the early stages, may not be associated with any obvious symptoms other than irregular vaginal bleeding or feeling pressure in abdomen or pelvic.
* The majority of patients with leiomyosarcoma remain asymptomatic for decades.
* General symptoms associated with cancer may occur including fatigue, fever, weight loss, malaise, and nausea and vomiting.
* The prognosis of patients with uterine sarcomas has not changed in recent decades because of rare nature of disease and late diagnosis.
* Patients with leiomyosarcoma have overall 5‐year survival rate of between 17.5% and 54.7% in various studies.

## Complications

[edit | edit source]

Leiomyosarcomas are aggressive tumors that potentially cause complications due to metastasis to other organs, some of the complications of uterine leiomyosarcoma are include the following:[4][5][6][6][7][8][9]

* Anxiety and stress because of uterine cancer
* Lockjaw and numbness in lips
* Dysphagia due to esophageal leiomyosarcoma metastasis
* Anemia due to metastasis to duodenum or cancer itself.
* Metastasis to lung and pulmonary symptoms due to that.
* Side effects of chemotherapy and radiation therapy such as sexual dysfunction.

## Prognosis

[edit | edit source]

The prognosis of leiomyosarcoma is poor and it depends upon different factors including site of tumor, size, and type, as well as the extent of tumor spread. Some patients with low grade tumors or with tumors that have not spread beyond stage I have better prognosis. In general, high-grade tumors that have spread widely throughout the body have less favorable survival rates. Some of these progostic factors that affect survival rates of patients with leiomyosarcoma include:[10]

* FIGO stage at the time of the initial diagnosis (survival after initial diagnosis has been reported to be 50% in stage 1 and stage 2 disease)
* Age at the time of diagnosis
* Mitotic count
* Tumor size (tumors greater than 5cm has worse prognosis)
* Adjuvant therapies such as chemotherapy and radiation

## References

[edit | edit source]

1. ↑ Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, Yordan E, Brady MF (February 1993). "Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study". Cancer. 71 (4 Suppl): 1702–9. PMID 8381710.
2. ↑ Gladdy, Rebecca A.; Qin, Li-Xuan; Moraco, Nicole; Agaram, Narasimhan P.; Brennan, Murray F.; Singer, Samuel (2013). "Predictors of Survival and Recurrence in Primary Leiomyosarcoma". Annals of Surgical Oncology. 20 (6): 1851–1857. doi:10.1245/s10434-013-2876-y. ISSN 1068-9265.
3. ↑ Koivisto-Korander, Riitta; Butzow, Ralf; Koivisto, Anna-Maija; Leminen, Arto (2008). "Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: Experience in Helsinki University Central Hospital 1990–2001". Gynecologic Oncology. 111 (1): 74–81. doi:10.1016/j.ygyno.2008.06.002. ISSN 0090-8258.
4. ↑ Keller, Nathan A.; Godoy, Heidi (2015). "Leiomyosarcoma of the Vagina: An Exceedingly Rare Diagnosis". Case Reports in Obstetrics and Gynecology. 2015: 1–4. doi:10.1155/2015/363895. ISSN 2090-6684.
5. ↑ . doi:10.1111/j.1442-2050.2012.01444.x. Epub 2012 Nov 16 Check `|doi=` value (help). Missing or empty `|title=` (help)
6. ↑ 6.0 6.1 Billingsley KG, Burt ME, Jara E, Ginsberg RJ, Woodruff JM, Leung DH, Brennan MF (May 1999). "Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival". Ann. Surg. 229 (5): 602–10, discussion 610–2. PMC 1420804. PMID 10235518.
7. ↑ Falk, Sandy J.; Dizon, Don S. (2013). "Sexual dysfunction in women with cancer". Fertility and Sterility. 100 (4): 916–921. doi:10.1016/j.fertnstert.2013.08.018. ISSN 0015-0282.
8. ↑ Hope, Isabel; Morton, Karen; Newlands, Carrie; Butler-Manuel, Simon; Madhuri, Thumuluru Kavitha (2017). "Lockjaw from a metastatic uterine leiomyosarcoma- case report and review of the literature". BMC Women's Health. 17 (1). doi:10.1186/s12905-017-0472-1. ISSN 1472-6874.
9. ↑ Fleet, M.; Mellon, A.F.; Lee, J.A.; Talbot, D.; Eastham, E.J.; Pearson, A.D.J. (1994). "Duodenal leiomyosarcoma presenting with iron deficiency anemia". Journal of Pediatric Surgery. 29 (12): 1601–1603. doi:10.1016/0022-3468(94)90233-X. ISSN 0022-3468.
10. ↑ Koivisto-Korander, Riitta; Butzow, Ralf; Koivisto, Anna-Maija; Leminen, Arto (2008). "Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: Experience in Helsinki University Central Hospital 1990–2001". Gynecologic Oncology. 111 (1): 74–81. doi:10.1016/j.ygyno.2008.06.002. ISSN 0090-8258.

Template:WikiDoc Sources